The authors hypothesized that replacement of the simultaneously lost GLP-2 could be a therapeutic agent for IBD, but it was not until GLP-1’s immunomodulatory actions were established that GLP-1 was considered a therapeutic agent for IBD independently of GLP-2 [46]. The gene discussed is GLP1R; the disease is inflammatory bowel disease.